You have free access to this content

Cancer

Cover image for Vol. 117 Issue 8

15 April 2011

Volume 117, Issue 8

Pages 1557–1784

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      Melanoma's deadly march to the brain : By what route, and can it be stopped? (pages 1560–1563)

      Megan Othus, James Moon and Kim Margolin

      Version of Record online: 10 NOV 2010 | DOI: 10.1002/cncr.25716

      The 3 articles reviewed in this issue of Cancer add to and update previously reported experience regarding the prognosis of melanoma patients diagnosed with brain metastases, but do not answer the important question of identifying which patients diagnosed with early melanoma will go on to develop this complication that most frequently determines the outcome in metastatic melanoma and how and when to best intervene therapeutically. If clinicians wish to use retrospective databases to help improve outcomes for these patients, then better biologic discriminators, based on careful clinico-pathologic correlational observations, need to be incorporated and then validated in large datasets to define useful prognostic subsets.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
      The implications of the 2010 patient protection and affordable care act and the health care and education reconciliation act on cancer care delivery (pages 1564–1574)

      Heidi W. Albright, Mark Moreno, Thomas W. Feeley, Ronald Walters, Marc Samuels, Alissa Pereira and Thomas W. Burke

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25725

      In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. Cancer is a major health problem in the United States and the leading cause of death for Americans under the age of 80. Therefore, cancer care providers need to be fully engaged in ongoing discussions regarding quality measurement and care delivery.

    2. You have free access to this content
      Use of standard markers and incorporation of molecular markers into breast cancer therapy : Consensus recommendations from an International Expert Panel (pages 1575–1582)

      Manfred Kaufmann, Lajos Pusztai and the Biedenkopf Expert Panel Members

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25660

      • original image

      Considerable uncertainty remains on new molecular markers in breast cancer in routine clinical decision making. An expert panel reviewed all available data, making consensus recommendations on the use of molecular markers in breast cancer management and their incorporation into future clinical trials.

    3. You have free access to this content
      Philadelphia chromosome-positive acute lymphoblastic leukemia : Current treatment and future perspectives (pages 1583–1594)

      Hun J. Lee, James E. Thompson, Eunice S. Wang and Meir Wetzler

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25690

      Imatinib has become a crucial element in therapy for patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL); however, patients can acquire resistance to imatinib rapidly, which highlights the limitations of imatinib as a single agent. The results from this extensive review of the literature indicated that integrating tyrosine kinase inhibitors (including imatinib, dasatinib, and nilotinib) and other targeted therapies into standard chemotherapeutic regimens with established antileukemic agents may substantially improve remission duration and the prognosis for patients with Ph-positive ALL.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer (pages 1595–1601)

      Jeffrey M. Albert, Ana M. Gonzalez-Angulo, Merih Guray, Aysegul Sahin, Welela Tereffe, Wendy A. Woodward, Eric A. Strom, Kelly K. Hunt, Susan L. Tucker and Thomas A. Buchholz

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25694

      • original image
      • original image
      • original image

      Patients with T1a,bN0 breast cancer that has only 1 positive hormone receptor have increased rates of locoregional recurrence compared with patients who have estrogen receptor-positive/progesterone receptor-positive disease, although this difference may be reduced or eliminated with systemic treatment. In contrast, the authors found no evidence of an increased rate of distant metastasis in these patients with favorable disease stage.

    2. You have free access to this content
      The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases (pages 1602–1611)

      Carey K. Anders, Allison M. Deal, C. Ryan Miller, Carmen Khorram, Hong Meng, Emily Burrows, Chad Livasy, Karen Fritchie, Matthew G. Ewend, Charles M. Perou and Lisa A. Carey

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25746

      • original image

      Brain metastases are commonly diagnosed among patients with triple-negative breast cancer, a subtype of breast cancer with a poor prognosis that is commonly diagnosed in premenopausal African-American women. However, it is not clear how much tumor subtype, race, and age each contribute to this poor outcome. This retrospective cohort study illustrates that the poor prognosis associated with triple-negative breast cancer brain metastases is independent of both young age and African-American race.

    3. You have free access to this content
      Prospective study of growth and development in older girls and risk of benign breast disease in young women (pages 1612–1620)

      Catherine S. Berkey, Walter C. Willett, A. Lindsay Frazier, Bernard Rosner, Rulla M. Tamimi and Graham A. Colditz

      Version of Record online: 15 FEB 2011 | DOI: 10.1002/cncr.25692

      Lower childhood BMI, taller adult height, and more rapid pubertal height growth were associated with higher risk of benign breast disease in young women. Age at menarche, adult BMI, and change in BMI from childhood to adulthood were not associated with risk.

    4. You have free access to this content
      Breast cancer recurrence diagnosis suspected on tumor marker rising : Value of whole-body 18FDG-PET/CT imaging and impact on patient management (pages 1621–1629)

      Laurence Champion, Etienne Brain, Anne-Laure Giraudet, Elise Le Stanc, Myriam Wartski, Véronique Edeline, Olivier Madar, Dominique Bellet, Alain Pecking and Jean-Louis Alberini

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25727

      • original image
      • original image

      The results from this study indicated that 18FDG-PET/CT imaging is an efficient technique to detect breast cancer recurrence suspected on tumor marker rising in asymptomatic patients.

    5. Endocrine Disease
      You have free access to this content
      MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy (pages 1630–1639)

      Erin E. Patterson, Alisha K. Holloway, Julie Weng, Tito Fojo and Electron Kebebew

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25724

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      This work identified microRNAs that are differentially expressed in malignant adrenocortical tumors as compared with benign tumors. Significantly, miR-483-5p appears to be a defining characteristic of adrenocortical malignancies, and expression of miR-483-5p can be used to accurately distinguish between benign and malignant adrenocortical tumors.

    6. Gastrointestinal Disease
      You have free access to this content
      Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use (pages 1640–1648)

      N. Jewel Samadder, Bhramar Mukherjee, Shu-Chen Huang, Jaeil Ahn, Hedy S. Rennert, Joel K. Greenson, Gad Rennert and Stephen B. Gruber

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25731

      A population-based study of 1921 cases of colorectal cancer (CRC) and 1921 matched controls evaluated the relationship between inflammatory bowel disease and risk of CRC, and assessed with risk was modified by statin or NSAID use. The risk of CRC was elevated 1.9-fold in patients with inflammatory bowel disease (IBD). Long-term statin use was associated with reduced risk of CRC in patients with IBD.

    7. Genitourinary Disease
      You have free access to this content
      DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma (pages 1649–1660)

      Hiroshi Hirata, Yuji Hinoda, Shahana Majid, Yi Chen, Mohd S. Zaman, Koji Ueno, Koichi Nakajima, Z. Laura Tabatabai, Nobuhisa Ishii and Rajvir Dahiya

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25666

      • original image
      • original image
      • original image
      • original image
      • original image

      Although the Wnt antagonist dickkopf homolog 4 (DKK4) did not induce apoptosis, it promoted renal cancer cell proliferation, invasion, and migration, probably through the noncanonical c-Jun-NH2 kinase or JNK pathway, which also increased matrix metalloproteinase-2 expression. Thus, the current findings contribute important information about the role of DKK4 in renal cancer cells.

    8. Gynecologic Oncology
      You have free access to this content
      Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer (pages 1661–1669)

      Siqing Fu, Wei Hu, Revathy Iyer, John J. Kavanagh, Robert L. Coleman, Charles F. Levenback, Anil K. Sood, Judith K. Wolf, David M. Gershenson, Maurie Markman, Bryan T. Hennessy, Razelle Kurzrock and Robert C. Bast Jr

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25701

      • original image
      • original image
      • original image
      • original image

      A hypomethylating agent, azacitidine, is able to reverse chemoresistance by re-expressing epigenetically silenced genes involved in apoptosis. To the authors' knowledge, the current study provides the first clinical evidence that azacitidine may partially reverse platinum resistance in patients with recurrent epithelial ovarian cancer through epigenetic modulation.

    9. Head and Neck Disease
      You have full text access to this OnlineOpen article
      Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer (pages 1670–1678)

      Turki Y. Alhazzazi, Pachiyappan Kamarajan, Nam Joo, Jing-Yi Huang, Eric Verdin, Nisha J. D'Silva and Yvonne L. Kapila

      Version of Record online: 29 NOV 2010 | DOI: 10.1002/cncr.25676

      • original image
      • original image
      • original image
      • original image
      • original image

      Oral squamous cell carcinoma (OSCC) accounts for >90% of all oral malignancies, and the 5-year survival rates (34% to 62.9%) have not changed in decades, underscoring the need for new therapeutic targets to treat oral cancer. The authors of this report identified a novel role for sirtuin-3 (SIRT3) in oral cancer carcinogenesis as a modulator of cell proliferation and survival, as supported by in vitro and in vivo findings that implicate SIRT3 as a new potential therapeutic target for treating oral cancer.

    10. You have free access to this content
      Longitudinal oncology registry of head and neck carcinoma (LORHAN) : Analysis of chemoradiation treatment approaches in the United States (pages 1679–1686)

      Stuart J. Wong, Paul M. Harari, Adam S. Garden, Marc Schwartz, Lisa Bellm, Amy Chen, Walter J. Curran, Barbara A. Murphy and K. Kian Ang

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25721

      LORHAN, a prospective national head and neck cancer database, was analyzed to give a snapshot of the current practice pattern in the United States for chemotherapy utilization, in conjunction with radiation, for head and neck cancer therapy. Induction chemotherapy is commonly used, but cisplatin-based chemoradiation remains the most common regimen.

    11. Melanoma
      You have free access to this content
      Prognostic factors for survival in melanoma patients with brain metastases (pages 1687–1696)

      Michael A. Davies, Ping Liu, Susan McIntyre, Kevin B. Kim, Nicholas Papadopoulos, Wen-Jen Hwu, Patrick Hwu and Agop Bedikian

      Version of Record online: 19 OCT 2010 | DOI: 10.1002/cncr.25634

      • original image
      • original image
      • original image
      • original image

      The authors reviewed more than 300 melanoma patients who developed brain metastases and investigated prognostic factors for survival. The date of diagnosis, pattern of involvement, and timing relative to extracranial metastases were found to be the most important predictors of overall survival; patients who had responded to prior systemic therapies for extracranial metastases had improved survival with systemic therapies for brain metastases.

    12. You have free access to this content
      Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma (pages 1697–1703)

      Thomas K. Eigentler, Adina Figl, Dietmar Krex, Peter Mohr, Cornelia Mauch, Knut Rass, Azize Bostroem, Oliver Heese, Oliver Koelbl, Claus Garbe, Dirk Schadendorf and on behalf of the Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25631

      • original image

      The overall survival of patients with brain metastases from malignant melanoma primarily depends on the number of metastases and pretreatment level of lactate dehydrogenase. In the case of a single brain metastasis, stereotactic radiotherapy or neurosurgical metastasectomy is by far the most important factor for improving survival.

    13. You have free access to this content
      A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group Study, N057E1 (pages 1704–1710)

      Lisa A. Kottschade, Vera J. Suman, Thomas Amatruda III, Robert R. McWilliams, Bassam I. Mattar, Daniel A. Nikcevich, Robert Behrens, Tom R. Fitch, Anthony J. Jaslowski and Svetomir N. Markovic

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25659

      • original image
      • original image

      The combination of carboplatin and ABI-007 appears to be well tolerated and provides promising antitumor activity as first-line therapy, with a response rate of 25.6% in patients with malignant melanoma. Although such regimens have not been formally compared in a randomized controlled study, the combination of ABI-007 and carboplatin is a viable option at least patients for who cannot tolerate conventional paclitaxel therapy.

    14. You have free access to this content
      Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival (pages 1711–1720)

      Jan Zakrzewski, Laurel N. Geraghty, Amy E. Rose, Paul J. Christos, Madhu Mazumdar, David Polsky, Richard Shapiro, Russell Berman, Farbod Darvishian, Eva Hernando, Anna Pavlick and Iman Osman

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25643

      • original image
      • original image

      Ulceration of the primary tumor was found to be the strongest predictor of melanoma brain metastases (B-Met) development and remained an independent predictor of decreased post-B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome.

    15. Neuro-Oncology
      You have free access to this content
      Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter : A multicenter study (pages 1721–1730)

      Kazuya Motomura, Atsushi Natsume, Yugo Kishida, Hiroyuki Higashi, Yutaka Kondo, Yoko Nakasu, Tatsuya Abe, Hiroki Namba, Kenji Wakai and Toshihiko Wakabayashi

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25637

      • original image
      • original image
      • original image
      • original image

      This study cataloged genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determined the correlation among clinical, genetic, and epigenetic profiles and clinical outcome. Addition of interferon-β for newly diagnosed primary GBM achieved a favorable outcome, particularly in patients with unmethylated MGMT promoter.

    16. Sarcoma
      You have free access to this content
      Periosteal osteosarcoma : A single-institution experience (pages 1731–1735)

      Marilena Cesari, Marco Alberghini, Daniel Vanel, Emanuela Palmerini, Eric L. Staals, Alessandra Longhi, Massimo Abate, Cristina Ferrari, Alba Balladelli and Stefano Ferrari

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25718

      • original image

      In this single-institution study, the authors examined the treatment of 33 patients who had periosteal osteosarcoma, a rare variant of osteosarcoma. The results indicated that surgery is the mainstay of treatment for these patients, and adjuvant chemotherapy is not required.

    17. You have free access to this content
      Addition of pamidronate to chemotherapy for the treatment of osteosarcoma (pages 1736–1744)

      Paul A. Meyers, John H. Healey, Alexander J. Chou, Leonard H. Wexler, Pamela R. Merola, Carol D. Morris, Michael P. Laquaglia, Michael G. Kellick, Sara J. Abramson and Richard Gorlick

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25744

      • original image
      • original image

      Bisphosphonates have activity against osteosarcoma in vitro. The addition of pamidronate to chemotherapy for the treatment of osteosarcoma is safe and does not impair the activity of chemotherapy.

    18. Discipline

      Disparities Research
      You have free access to this content
      Effectiveness of a clinic-based colorectal cancer screening promotion program for underserved Hispanics (pages 1745–1754)

      Gloria D. Coronado, Ilya Golovaty, Gary Longton, Lisa Levy and Ricardo Jimenez

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25730

      • original image
      • original image

      Hispanics in the United States are less likely than other groups to receive screening services for colorectal cancer. We enrolled 501 Latino patients aged 50-79 in a three-arm individually randomized clinic-based colorectal screening intervention. Postintervention fecal occult blood test (FOBT) screening percentages were: 31% in the mailed FOBT and outreach arm, 26% in the mailed FOBT arm only, and 2% in the usual care arm.

    19. You have free access to this content
      Geographic variation of racial/ethnic disparities in colorectal cancer testing among medicare enrollees (pages 1755–1763)

      Thomas J. Semrad, Daniel J. Tancredi, Laura-Mae Baldwin, Pamela Green and Joshua J. Fenton

      Version of Record online: 10 JAN 2011 | DOI: 10.1002/cncr.25668

      • original image
      • original image
      • original image

      Significant geographic variation in colorectal cancer testing among black and Asian/Pacific Islander Medicare enrollees results in variable white versus nonwhite disparities across US regions. In the Medicare population, variation in racial/ethnic disparities in colorectal cancer testing stems principally from regional differences in test use among nonwhites.

    20. Pediatric Oncology
      You have free access to this content
      Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts (pages 1764–1774)

      Pooja Hingorani, Wendong Zhang, Juan Lin, Laibin Liu, Chandan Guha and E. Anders Kolb

      Version of Record online: 8 NOV 2010 | DOI: 10.1002/cncr.25741

      • original image
      • original image
      • original image
      • original image
      • original image

      Systemic administration of reovirus is active in a broad panel of pediatric sarcoma cell lines and tumor xenografts, and the antitumor effect is enhanced in combination with other cytotoxic agents.

    21. Symptom Control and Palliative Care
      You have free access to this content
      Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy (pages 1775–1782)

      Rachel A. Murphy, Marina Mourtzakis, Quincy S.C. Chu, Vickie E. Baracos, Tony Reiman and Vera C. Mazurak

      Version of Record online: 28 FEB 2011 | DOI: 10.1002/cncr.25709

      • original image

      Fish oil supplementation resulted in the maintenance of weight, skeletal muscle, and fat mass. Fish oil supplementation provides a benefit over standard of care in patients with lung cancer who are receiving first-line chemotherapy.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION